Literature analysis of cutaneous adverse reactions induced by tislelizumab

References

• Baumeister SH, Freeman GJ, Dranoff G, et al. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol. 2016;34(1):539–573. doi:10.1146/annurev-immunol-032414-112049.
   PubMed Web of Science ®Google Scholar
• Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19(3):345–361. doi:10.1007/s40257-017-0336-3.
   PubMed Web of Science ®Google Scholar
• Curry JL, Tetzlaff MT, Nagarajan P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017;44(2):158–176. doi:10.1111/cup.12858.
   PubMed Web of Science ®Google Scholar
• Malviya N, Tattersall IW, Leventhal J, et al. Cutaneous immune-related adverse events to checkpoint inhibitors. Clin Dermatol. 2020;38(6):660–678. doi:10.1016/j.clindermatol.2020.06.011.
   PubMed Web of Science ®Google Scholar
• Dang YC, Liu HB, Wang Z, et al. Cutaneous adverse events associated with PD-1 inhibitor-based therapy in patients with-non-small-cell lung cancer. Future Oncol. 2022;18(34):3853–3861. doi:10.2217/fon-2022-0888.
   Web of Science ®Google Scholar
• Yao XY, Dong XZ, Hou GJ, et al. A case of immune-related Stevens-Johnson syndrome caused by tislelizumab]. Chin J Hospital Pharm. 2023;43(02):237–238. doi:10.13286/j.1001-5213.2023.02.21.
   Google Scholar
• Deng AQ, Yen XQ, Zhu QY, et al. One case report of toxic epidermal necrolysis associated with tislelizumab]. Chin J Hospital Pharm. 2021;41(19):2039–2040. doi:10.13286/j.1001-5213.2021.19.22.
   Google Scholar
• Su Y, Wang QQ, Wang MR, et al. One case report of immune checkpoint inhibitor-associated toxic epidermal necrolysis. China Clin Pract Med. 2022;13(2):77–78. doi:10.3760/cma.j.cn115570-20220112-00075.
   Google Scholar
• Cheng MX, Chen YS, Zhao YC, et al. One case report of toxic epidermal necrolysis drug eruption caused by tislelizumab. Herald Med. 2022;41(4):581–583. doi:10.3870/j.issn.1004-0781.2022.04.027.
   Google Scholar
• Guo HX, Chang HL, Feng HJ. Immune-associated toxic epidermal necrolysis: a case report and literature review. Chin J Cancer Biotherapy. 2022;29(11):1006–1009. doi:10.3872/j.issn.1007-385x.2022.11.010.
   Google Scholar
• Sun LD, Ji SX, Zhang D, et al. Stevens-Johnson syndrome caused by tislelizumab and related pharmaceutical care. Pharmaceut J Chin People’s Liberation Army. 2022;35(3):252–254. doi:10.3969/j.issn.1008-9926.2022.03.016.
   Google Scholar
• Liu HW, Yang JY, Yan ZW. Epidermolysis bullosa induced by tislelizumab. Strait Pharmaceut J. 2022;34(6):149–151. doi:10.3969/j.issn.1006-3765.2022.06.044.
   Google Scholar
• Fang ZJ, Wang LM, Li JJ. Psoriasiform eruption in patients with advanced lung cancer treated with a PD–1 inhibitor (tislelizumab): a case report and literature review. China J Leprosy Skin Diseases. 2022;38(3):161–163. doi:10.12144/zgmfskin202203161.
   Google Scholar
• Li SY, Tong JB, Cao XW, et al. One case of exfoliative dermatitis related to tislelizumab. Chin J Hospital Pharm. 2022;42(7):765–766. doi:10.13286/j.1001-5213.2022.07.20.
   Google Scholar
• Kerkemeyer KLS, Lai FYX, Mar A. Lichen planus pemphigoides during therapy with tislelizumab and sitravatinib in a patient with metastatic lung cancer. Australas J Dermatol. 2020;61(2):180–182. doi:10.1111/ajd.13214.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang M, Xie J, et al. Pemphigus Herpetiformis-Type drug reaction caused by programmed cell death protein-1 inhibitor treatment. Clin Cosmet Investig Dermatol. 2021;14:1125–1129. doi:10.2147/CCID.S330354.
   PubMed Web of Science ®Google Scholar
• Lin YF, Xu YH, Dong DD, et al. Radiation memory dermatitis caused by tislelizumab. Chin J Dermatovenereol. 2023;37(07):823–824. doi:10.13735/j.cjdv.1001-7089.202208124.
   Google Scholar
• Rao H, Guo Z, Wen X, et al. Case report: immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: a report of three cases and a pooled analysis of individual patient data. Front Oncol. 2022; 12:1099108. doi:10.3389/fonc.2022.1099108.
   PubMed Web of Science ®Google Scholar
• Cao MM, Chen WQ. Epidemiology of cancer in China and the current status of prevention and control. Chin J Clin Oncol. 2019;46(03):145–149. doi:10.3969/j.issn.1000-8179.2019.03.283.
   Google Scholar
• Jacobsen A, Olabi B, Langley A, et al. Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. Cochrane Database Syst Rev. 2022;3(3):CD013130. doi:10.1002/14651858.CD013130.pub2.
   PubMedGoogle Scholar
• Noe MH, Micheletti RG. Systemic interventions for treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis: summary of a cochrane review. JAMA Dermatol. 2022;158(12):1436–1437. doi:10.1001/jamadermatol.2022.4543.
   PubMed Web of Science ®Google Scholar
• Patel PU, Levell NJ. Erythroderma and acute skin failure. Medicine. 2021;49(7):421–427. doi:10.1016/j.mpmed.2021.04.005.
   Google Scholar
• Coleman EL, Olamiju B, Leventhal JS. The life-threatening eruptions of immune checkpoint inhibitor therapy. Clin Dermatol. 2020;38(1):94–104. doi:10.1016/j.clindermatol.2019.10.015.
   PubMed Web of Science ®Google Scholar
• Cutroneo P, Ingrasciotta Y, Isgro V, et al. Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors. Dermatol Ther. 2021;34(2):e14830. doi:10.1111/dth.14830.
   PubMed Web of Science ®Google Scholar
• Voudouri D, Nikolaou V, Laschos K, et al. Anti-PD1/PDL1 induced psoriasis. Curr Probl Cancer. 2017;41(6):407–412. doi:10.1016/j.currproblcancer.2017.10.003.
   PubMed Web of Science ®Google Scholar
• Law-Ping-Man S, Martin A, Briens E, et al. Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer. Rheumatology. 2016;55(11):2087–2089. doi:10.1093/rheumatology/kew281.
   PubMed Web of Science ®Google Scholar
• Uenami T, Hosono Y, Ishijima M, et al. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: a case report. Lung Cancer. 2017;109:42–44. doi:10.1016/j.lungcan.2017.04.019.
   PubMed Web of Science ®Google Scholar
• Liu RC, Consuegra G, Chou S, et al. Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers. Clin Exp Dermatol. 2019;44(6):643–646. doi:10.1111/ced.13867.
   PubMed Web of Science ®Google Scholar
• Yin ES, Totonchy MB, Leventhal JS. Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: a novel finding. JAAD Case Rep. 2017;3(2):90–92. doi:10.1016/j.jdcr.2016.10.008.
   PubMedGoogle Scholar
• Larsabal M, Marti A, Jacquemin C, et al. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol. 2017;76(5):863–870. doi:10.1016/j.jaad.2016.10.044.
   PubMed Web of Science ®Google Scholar
• Emre S, Demirseren DD, Unal E, et al. Recurrent radiation recall dermatitis triggered by radiological procedures in a patient with breast cancer. Australas J Dermatol. 2019;60(4):308–310. doi:10.1111/ajd.13037.
   PubMed Web of Science ®Google Scholar
• Vern-Gross TZ, Kowal-Vern A. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis syndrome in patients undergoing radiation therapy: a literature review. Am J Clin Oncol. 2014;37(5):506–513. doi:10.1097/COC.0b013e31825d5835.
   PubMed Web of Science ®Google Scholar
• van Seggelen WO, De Vos FY, Rockmann H, et al. Occurrence of an abscopal radiation recall phenomenon in a glioblastoma patient treated with nivolumab and Re-Irradiation. Case Rep Oncol. 2019;12(3):896–900. doi:10.1159/000504698.
   PubMed Web of Science ®Google Scholar
• Hubner F, Langan EA, Recke A. Lichen planus pemphigoides: from lichenoid inflammation to autoantibody-mediated blistering. Front Immunol. 2019;10:1389. doi:10.3389/fimmu.2019.01389.
   PubMed Web of Science ®Google Scholar
• Sato Y, Fujimura T, Mizuashi M, et al. Lichen planus pemphigoides developing from patient with non-small-cell lung cancer treated with nivolumab. J Dermatol. 2019;46(10):e374–e375. doi:10.1111/1346-8138.14906.
   PubMed Web of Science ®Google Scholar
• Schmidgen MI, Butsch F, Schadmand-Fischer S, et al. Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic melanoma. J Dtsch Dermatol Ges. 2017;15(7):742–745. doi:10.1111/ddg.13272.
   Web of Science ®Google Scholar
• Boyle MM, Ashi S, Puiu T, et al. Lichen planus pemphigoides associated with PD-1 and PD-L1 inhibitors: a case series and review of the literature. Am J Dermatopathol. 2022;44(5):360–367. doi:10.1097/DAD.0000000000002139.
   PubMed Web of Science ®Google Scholar
• Hayder F, Bahloul E, Sellami K, et al. Pemphigus herpetiformis in a 4-year-old child: case report and review of the literature. Clin Case Rep. 2022;10(3):e05567. doi:10.1002/ccr3.5567.
   PubMed Web of Science ®Google Scholar
• Costa LMC, Cappel MA, Keeling JH. Clinical, pathologic, and immunologic features of pemphigus herpetiformis: a literature review and proposed diagnostic criteria. Int J Dermatol. 2019;58(9):997–1007. doi:10.1111/ijd.14395.
   PubMed Web of Science ®Google Scholar
• Morais KL, Miyamoto D, Orfali RL, et al. Increased expression of in situ IL-31RA and circulating CXCL8 and CCL2 in pemphigus herpetiformis suggests participation of the IL-31 family in the pathogenesis of the disease. J Eur Acad Dermatol Venereol. 2020;34(12):2890–2897. doi:10.1111/jdv.16730.
   PubMed Web of Science ®Google Scholar
• Buquicchio R, Mastrandrea V, Strippoli S, et al. Case report: autoimmune pemphigus vulgaris in a patient treated with cemiplimab for multiple locally advanced cutaneous squamous cell carcinoma. Front Oncol. 2021;11:691980. doi:10.3389/fonc.2021.691980.
   PubMed Web of Science ®Google Scholar
• Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:190–209. doi:10.1016/j.ejca.2016.02.025.
   PubMed Web of Science ®Google Scholar
• Wang LL, Patel G, Chiesa-Fuxench ZC, et al. Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy. JAMA Dermatol. 2018;154(9):1057–1061. doi:10.1001/jamadermatol.2018.1912.
   PubMed Web of Science ®Google Scholar
• Guidelines of Chinese Society of Clinical Oncology (CSCO): Management of immune checkpoint inhibitor-related toxicity. Beijing, China: People’s Medical Publishing House; 2021.
   Google Scholar
• Sanlorenzo M, Vujic I, Daud A, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151(11):1206–1212. doi:10.1001/jamadermatol.2015.1916.
   PubMed Web of Science ®Google Scholar
• Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45–51. doi:10.1001/jamadermatol.2015.2707.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Thompson JA. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline summary. J Oncol Pract. 2018;14(4):247–249. doi:10.1200/JOP.
   PubMed Web of Science ®Google Scholar